Virpax Pharmaceuticals Inc (NASDAQ: VRPX)’s stock price has decreased by -25.09 compared to its previous closing price of 0.17. However, the company has seen a -30.44% decrease in its stock price over the last five trading sessions. businesswire.com reported 2025-03-07 that BERWYN, Pa.–(BUSINESS WIRE)–Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, is looking to use Molecular Envelope Technology (MET) or a similar technology to deliver a mRNA COVID vaccine. Virpax currently uses its MET for Envelta (NES100) and NobrXiol (VRP324). The Company will look t.
Is It Worth Investing in Virpax Pharmaceuticals Inc (NASDAQ: VRPX) Right Now?
Moreover, the 36-month beta value for VRPX is 1.09. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for VRPX is 26.13M and currently, short sellers hold a 3.66% of that float. On March 18, 2025, VRPX’s average trading volume was 5.57M shares.
VRPX’s Market Performance
VRPX’s stock has seen a -30.44% decrease for the week, with a -61.20% drop in the past month and a -57.93% fall in the past quarter. The volatility ratio for the week is 6.75%, and the volatility levels for the past 30 days are at 11.65% for Virpax Pharmaceuticals Inc The simple moving average for the past 20 days is -39.55% for VRPX’s stock, with a -79.77% simple moving average for the past 200 days.
VRPX Trading at -53.63% from the 50-Day Moving Average
After a stumble in the market that brought VRPX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -97.38% of loss for the given period.
Volatility was left at 11.65%, however, over the last 30 days, the volatility rate increased by 6.75%, as shares sank -59.19% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -66.22% lower at present.
During the last 5 trading sessions, VRPX fell by -30.49%, which changed the moving average for the period of 200-days by -82.67% in comparison to the 20-day moving average, which settled at $0.2094. In addition, Virpax Pharmaceuticals Inc saw -66.68% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for VRPX
The total capital return value is set at 13.22. Equity return is now at value -2364.82, with -215.80 for asset returns.
Currently, EBITDA for the company is -12.08 billion with net debt to EBITDA at 0.13. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.63.
Conclusion
To wrap up, the performance of Virpax Pharmaceuticals Inc (VRPX) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
